pandem
liter
left
world
breathless
chase
pharmacotherapi
vaccin
approv
like
year
away
novel
drug
earli
clinic
trial
repurpos
exist
drug
take
center
stage
potenti
drug
discuss
geopolit
global
scientif
commun
hydroxychloroquin
hcq
intend
systemat
weigh
analyz
exist
evid
hcq
light
publish
preprint
data
avail
far
registri
unit
state
china
ictrp
electron
search
studi
use
hcq
patient
preproof
articl
repositori
like
medrxiv
biorxiv
chemrxiv
also
includ
search
literatur
critic
apprais
total
articl
avail
th
april
articl
relev
three
invitro
studi
two
open
label
nonrandom
trial
two
open
label
random
control
trial
one
followup
studi
three
review
ten
short
commun
clinic
trial
regist
three
clinic
trial
registri
analyz
hcq
seem
effici
inhibit
invitro
cell
line
lack
strong
evid
human
studi
invitro
cell
cultur
base
data
viral
inhibit
suffic
use
hydroxychloroquin
patient
current
literatur
show
inadequ
low
level
evid
human
studi
scarciti
safeti
efficaci
data
warrant
medic
commun
health
care
agenc
govern
across
world
widespread
use
hcq
prophylaxi
treatment
robust
evid
becom
avail
ongo
coronaviru
diseas
covid
pandem
affect
countri
world
unimagin
infecti
diseas
morbid
mortal
sinc
first
detect
china
late
decemb
spread
countriesterritori
report
local
transmiss
happen
across
world
per
april
total
confirm
case
death
due
worldwid
howev
specif
drug
approv
treatment
affect
countri
fight
everyday
flatten
curv
rigor
public
health
measur
polit
resolut
world
eagerli
look
vaccin
specif
treatment
recent
updat
indic
vaccin
quest
least
year
away
build
experi
past
ebola
mer
pandem
variou
human
trial
novel
pharmacotherapeut
progress
drug
remdesivir
favipiravir
exploratori
phase
clinic
trial
need
time
complet
phase
clinic
trial
unpreced
time
pursuit
repurpos
exist
drug
treatment
sarscoronaviru
infect
urgent
basi
drug
chloroquin
hydroxychloroquin
lopinavir
ritonavir
human
immunoglobulin
arbidol
oseltamivir
methylprednisolon
bevacizumab
interferon
tradit
chines
medicin
aim
reposit
treatment
forerunn
among
antimalari
drug
chloroquin
hydroxychloroquin
use
extens
treatment
malaria
elsewher
sinc
mani
decad
drug
deriv
exhibit
wide
rang
invitro
activ
virus
wide
clinic
usag
experi
afford
feasibl
bulk
product
addit
advantag
antivir
efficaci
attribut
mani
differ
mechan
studi
demonstr
chloroquin
confer
consider
broadspectrum
antivir
effect
interf
fusion
process
virus
increas
local
ph
mechan
may
includ
rais
endosom
ph
host
cell
therebi
inhibit
autolysosom
fusion
disrupt
enzym
need
viral
replic
hydroxychloroquin
hcq
synthes
nhydroxyethyl
side
chain
substitut
chloroquin
modif
render
hcq
solubl
chloroquin
may
confer
advantag
rel
lesser
toxic
similar
chloroquin
hcq
increas
ph
confer
antivir
activ
although
antimalari
activ
hcq
equival
chloroquin
hcq
prefer
chloroquin
owe
lower
ocular
toxic
also
use
treatment
rheumatoid
arthriti
chronic
discoid
lupu
erythematosu
system
lupu
erythematosu
addit
endosom
ph
increas
mention
hcq
also
said
inhibit
termin
glycosyl
receptor
consid
target
sarscov
cell
entri
nonglycosyl
receptor
might
interact
ineffici
spike
protein
thu
inhibit
viral
entri
myriad
mechan
hcq
rel
lesser
toxic
profil
compar
chloroquin
make
attract
candid
pursuit
drug
reposit
highli
demand
scenario
huge
unmet
need
steepli
increas
morbid
mortal
mani
govern
bodi
expert
panel
recommend
use
chloroquin
hcq
prophylaxi
treatment
recent
geopolit
media
coverag
possibl
drug
usag
caus
huge
stir
expect
among
laymen
medic
fratern
alik
lead
countri
engag
mass
product
export
import
drug
situat
urgenc
need
explor
current
literatur
critic
analyz
exist
evid
intend
conduct
systemat
search
analysi
current
literatur
propos
find
electron
search
publish
literatur
done
independ
author
find
role
hcq
diseas
pubm
ovid
medlin
embas
googl
scholar
databas
search
exist
literatur
th
april
clinic
trial
registri
unit
state
clinicaltrialsgov
chines
clinic
trial
registri
intern
clinic
trial
registri
platform
ictrp
search
ongo
regist
studi
preprintpreproof
articl
repositori
like
biorxiv
medrxiv
chemrxiv
search
search
word
includ
mesh
term
hydroxychloroquin
hcq
coronaviru
search
term
use
variou
combin
per
feasibl
differ
databas
view
possibl
limit
data
googl
scholar
search
term
kept
flexibl
encompass
wider
literatur
captur
potenti
relev
studi
languag
time
studi
type
demograph
filter
use
search
expans
done
use
snowbal
method
appli
author
refer
select
public
public
select
analysi
includ
abstract
origin
research
invitro
experiment
studi
observ
studi
controlleduncontrol
trial
review
articl
editori
letter
editor
expert
opinion
perspect
consensu
statementspublish
sinc
incept
till
april
news
item
magazin
piec
duplic
paper
articl
without
mention
role
hcq
infect
use
hcq
condit
exclud
search
databas
clinic
trial
registri
unit
state
clinicaltrialsgov
chines
clinic
trial
registri
ictrp
use
search
term
hydroxychloroquin
hcq
plaquenil
novel
corona
viru
ncov
identif
elimin
duplic
appear
clinic
trial
found
regist
databas
scan
analyz
filter
nonrecruit
inact
cancel
trial
final
yield
random
control
trial
rct
current
undergo
activ
recruit
treatment
hcq
preprint
server
databas
biorxiv
medrxiv
chemrxiv
search
preproof
nonpeer
review
unpublish
approv
await
studi
articl
recogn
author
alreadi
work
publish
articl
current
topic
includ
relev
studi
analysi
screen
articl
done
independ
investig
accord
titl
abstract
summari
conclus
relev
articl
decid
independ
read
analysi
full
text
public
discrep
relev
solv
mutual
consensu
elabor
discuss
relev
data
extract
select
articl
pertin
portion
studi
identifi
tabul
present
form
tabl
descript
summari
narr
summari
expert
opinion
clinic
statement
critic
apprais
per
joanna
brigg
institut
jbi
critic
checklist
mcarthur
et
al
infer
interpret
discuss
per
factual
data
balanc
conclus
drawn
accordingli
random
clinic
trial
activ
recruit
analyz
collect
public
avail
inform
variou
clinic
trial
databas
flow
chart
articl
select
shown
fig
total
articl
identifi
initi
search
databas
april
follow
screen
titl
abstract
remov
duplic
articl
relev
three
invitro
studi
two
open
label
non
random
trial
two
open
label
rct
one
followup
studi
three
review
ten
short
commun
select
data
extract
analys
identifi
clinic
trial
regist
three
clinic
trial
registri
databas
method
screen
analysi
yield
rct
current
undergo
activ
recruit
preprint
server
yield
four
clinic
studi
includ
follow
studi
retrospect
safeti
studi
rapid
review
chloroquin
hcq
patient
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
rel
lesser
toxic
profil
fewer
drugdrug
interact
make
hcq
attract
candid
test
antivir
properti
variou
broad
spectrum
antivir
mechan
hcq
propos
viz
chang
ph
surfac
cell
membran
inhibit
nucleic
acid
replic
glycosyl
viral
protein
disrupt
viru
assembl
interrupt
viral
transport
inhibit
viral
releas
etc
previous
sar
outbreak
hcq
shown
exhibit
antisar
cov
effect
invitro
studi
background
yao
et
al
assess
pharmacolog
activ
chloroquin
hydroxychloroquin
use
infect
vero
cell
continu
part
studi
simul
physiologicallybas
pharmacokinet
model
pbpk
vitro
data
obtain
research
found
hcq
potent
chloroquin
inhibit
sar
vitro
base
pbpk
extrapol
recommend
load
dose
mg
twice
daili
hcq
sulfat
given
oral
follow
mainten
dose
mg
given
twice
daili
day
anoth
correspond
report
letter
invitro
studi
liu
et
al
investig
use
cell
compar
antivir
activ
chloroquin
versu
hcq
determin
differ
multipl
infect
moi
quantif
viral
rna
copi
number
found
maxim
effect
concentr
hcq
significantli
higher
chloroquin
hcq
effici
inhibit
infect
vitro
previous
french
research
demonstr
chloroquin
hcq
effect
inhibit
human
felin
sar
cov
infect
vero
cell
hcq
significantli
higher
chloroquin
invitro
studi
use
cell
cultur
model
demonstr
consider
anticorona
viral
activ
hcq
particularli
sar
tabl
posit
background
success
invitro
data
situat
emerg
epidem
chines
author
issu
consensu
statement
use
chloroquin
patient
earliest
data
chloroquin
administr
human
came
variou
part
china
februari
collect
report
publish
form
exploratori
report
letter
gao
et
al
author
report
clinic
experi
data
treat
patient
chloroquin
variou
locat
mention
chloroquin
reduc
durat
ill
improv
pneumonia
pulmonari
imag
chang
posit
patient
author
also
recommend
drug
includ
guidelin
issu
nation
health
commiss
china
use
drug
larger
popul
pertin
note
data
brief
report
ongo
studi
multipl
set
first
empir
evid
use
hcq
human
obtain
small
rct
conduct
chen
j
et
al
adult
patient
treatment
group
receiv
hcq
day
standard
care
given
control
group
primari
outcom
nasopharyng
swab
test
result
day
investig
found
differ
treatment
control
group
number
patient
test
neg
day
vs
durat
ill
differ
significantli
p
one
drop
seven
three
treatment
group
four
control
advers
event
author
conclud
good
prognosi
larger
sampl
size
better
endpoint
need
investig
effect
openlabel
nonrandom
clinic
trial
conduct
gautret
et
al
franc
patient
diagnos
hcq
dose
three
time
daili
given
patient
day
addit
six
patient
group
receiv
azithromycin
mg
day
day
prevent
bacteri
superinfect
control
group
receiv
standard
care
primari
outcom
detect
rna
nasopharyng
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
sampl
author
report
patient
treatment
group
significantli
differ
detect
control
day
post
initi
hcq
treat
patient
virolog
cure
compar
control
group
p
conclud
hcq
treatment
significantli
associ
viral
load
reductiondisappear
patient
effect
reinforc
azithromycin
tabl
studi
group
wuhan
univers
china
conduct
rct
demonstr
efficaci
hcq
patient
patient
random
hcq
day
includ
standard
care
compar
standard
care
alon
time
taken
clinic
recoveri
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ttcr
clinic
characterist
radiolog
result
assess
baselin
day
treatment
hcq
research
report
ttcr
bodi
temperatur
recoveri
time
cough
remiss
time
significantli
shorten
hcq
treatment
group
besid
larger
proport
patient
improv
pneumonia
hcq
treatment
group
compar
control
group
four
patient
control
group
progress
sever
ill
research
conclud
hcq
significantli
shorten
ttcr
promot
resolut
pneumonia
patient
sixday
pilot
uncontrol
noncompar
observ
followup
studi
conduct
french
investig
assess
clinic
microbiolog
effect
combin
hcq
azithromycin
patient
investig
report
patient
two
yr
old
succumb
ill
yr
old
need
icu
show
clinic
improv
combin
therapi
qpcr
test
show
rapid
fall
nasopharyng
viral
patient
neg
day
day
respect
respiratori
sampl
neg
viru
cultur
day
research
urg
evalu
combin
strategi
treat
patient
earli
cours
avoid
spread
diseas
imit
previou
nonrandom
open
label
studi
gautret
et
al
anoth
group
french
investig
intend
evalu
rapid
antivir
clearanc
clinic
benefit
combin
hcq
azithromycin
patient
sever
research
prospect
assess
virolog
clearanc
clinic
outcom
patient
use
similar
dosag
regimen
hcq
mgd
day
azithromycin
mg
day
mg
day
use
gautret
et
al
note
contrast
previou
find
current
studi
patient
except
one
death
remain
posit
rna
day
treatment
initi
one
patient
die
within
day
two
transfer
icu
one
patient
drop
due
prolong
qt
interv
investig
conclud
evid
strong
antivir
activ
clinic
benefit
combin
hcq
azithromycin
treatment
hospit
patient
sever
retrospect
studi
group
american
research
report
increas
qt
interv
patient
treat
hydroxychloroquineazithromycin
combin
author
note
patient
increas
qtc
greater
patient
show
qtc
increas
greater
comment
develop
acut
renal
failur
therapi
could
strong
predictor
extrem
qtc
prolong
tabl
tabl
summari
preprint
articl
report
use
hcq
treatment
patient
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
mani
ongo
rct
conduct
studi
effect
hcq
compar
placebo
rct
parallel
design
arm
hcq
azithromycin
rct
robust
trial
design
quadrupl
mask
strong
endpoint
rct
advanc
phase
clinic
trial
studi
larg
sampl
size
measur
effect
higher
strength
confid
studi
consid
safeti
endpoint
main
outcom
measur
rct
also
test
antiretrovir
drug
like
lopinavirritonavir
emtricitabinetenofovir
along
hcq
arm
three
month
detect
china
late
decemb
novel
sar
infect
spread
almost
countri
world
far
threaten
biggest
pandem
modern
time
nearli
two
million
infect
death
grow
alarm
rate
specif
treatment
import
requir
world
hydroxycholoroquin
rel
better
safeti
profil
choloroquin
possibl
better
antivir
efficaci
offer
compel
hope
choic
time
desper
midst
pandem
systemat
search
variou
databas
clinic
trial
registri
evalu
evid
previou
outbreak
sar
invitro
studi
demonstr
anticorona
viral
effect
hcq
choloroquin
recent
chines
research
conduct
invitro
studi
cell
line
demonstr
potenti
antivir
activ
hcq
compar
chloroquin
relev
note
studi
basi
initi
opinion
gener
consensu
statement
given
variou
panel
across
world
earli
stage
current
pandem
found
scarciti
well
conduct
adequ
report
human
studi
hcq
use
agreement
author
similar
find
lack
literatur
regard
earliest
nonempir
evid
came
china
form
report
letter
patient
covid
pneumonia
show
clinic
improv
chang
imag
find
chloroquin
administr
pertin
note
letter
brief
report
ongo
mani
trial
variou
locat
china
neither
mention
specif
data
regard
intervent
studi
design
studi
popul
outcom
measur
advers
event
discuss
encount
translat
anoth
chines
rct
hcq
compar
standard
care
patient
investig
find
signific
differ
treatment
control
group
nasopharyng
swab
neg
durat
ill
studi
open
label
trial
small
sampl
size
high
risk
confound
select
bia
author
agre
primari
end
point
weak
robust
end
point
larger
sampl
size
requir
establish
effect
gautret
et
al
non
random
clinic
trial
patient
report
viral
load
reduct
hcq
reinforc
azithromycin
studi
major
limit
form
small
sampl
size
absenc
random
mask
lack
intent
treat
analysi
long
term
follow
clinic
endpoint
outcom
measur
among
preprint
nonpeer
review
studi
rct
chen
z
et
al
explor
hcq
azithromycin
patient
report
signific
improv
time
clinic
recoveri
radiolog
find
howev
sampl
size
studi
small
risk
select
bia
omiss
sever
ill
patient
patient
organ
dysfunct
confound
bia
high
author
involv
patient
prolong
qt
interv
comment
safeti
profil
treatment
brief
endpoint
includ
viral
rna
clearanc
lab
investig
followup
report
studi
noncompar
observ
french
followup
studi
patient
report
respiratori
sampl
neg
viru
cultur
day
studi
involv
mild
ill
patient
report
advers
effect
profil
uncontrol
observ
studi
strength
evid
tend
low
contrast
similar
studi
franc
imit
dosag
regimen
previou
french
non
random
open
label
studi
observ
evid
rapid
viral
reduct
clinic
benefit
combin
therapi
hcq
azithromycin
pertin
note
studi
conduct
patient
sever
also
search
identifi
analyz
clinic
trial
databas
explor
ongo
activ
clinic
trial
supplementari
tabl
found
relev
clinic
trial
mani
trial
among
advanc
phase
trial
expect
complet
near
futur
earlier
regist
chines
clinic
trial
expect
come
definit
result
next
week
also
robust
design
rct
elsewher
world
expect
produc
interim
result
shortli
henceforth
supplementari
tabl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
appropri
note
none
publish
studi
hcq
emphas
advers
effect
toxic
profil
drug
treat
patient
chen
z
et
al
report
two
advers
event
howev
due
small
sampl
size
difficult
attribut
hcq
even
though
hcq
rel
better
safeti
profil
chloroquin
owe
prolong
pharmacokinet
hour
half
life
gradual
elimin
potenti
caus
variou
advers
event
rang
commonli
seen
gastrointestin
upset
chronic
retin
toxic
seriou
advers
effect
like
fulmin
hepat
failur
sever
cutan
advers
reaction
import
advers
effect
hcq
cardiac
conduct
defect
ventricular
arrhythmia
qt
prolong
arrhythmia
precipit
concomit
use
azithromycin
small
absolut
risk
cardiovascular
death
seen
associ
significantli
azithromycin
compar
fluoroquinolon
import
note
overdos
poison
hcq
difficult
treat
caution
warrant
patient
hepat
renal
dysfunct
regular
ecg
monitor
advis
patient
cardiovascular
diseas
irrat
use
gener
popul
without
credibl
evid
may
pose
greater
risk
benefit
best
knowledg
systemat
review
comprehens
explor
analysi
exist
literatur
topic
till
date
review
limit
rigor
due
scarc
exist
data
divers
studi
type
avail
rapidli
emerg
knowledg
base
pose
possibl
studi
particularli
unpublishedund
peerreview
remain
uncaptur
howev
tri
best
mitig
allow
broadest
search
term
includ
mani
databas
repositori
also
tri
comprehens
analyz
assess
exist
data
critic
len
factual
judgment
background
believ
expert
opinion
clinic
consensu
statement
given
variou
intern
author
use
hcq
either
prophylaxi
high
risk
individu
healthcar
profession
emerg
treatment
patient
lack
strong
evid
base
invitro
cell
cultur
base
data
viral
inhibit
suffic
use
hydroxychloroquin
patient
current
literatur
show
scant
low
level
evid
human
studi
understand
due
urgenc
unmet
need
pandem
variou
expert
guidanc
consensu
statement
recommend
empir
use
hcq
howev
stage
due
insuffici
evid
efficaci
safeti
reason
suggest
use
hcq
prophylaxi
gener
popul
well
health
care
worker
consid
toxic
profil
chanc
overdos
poison
pose
seriou
health
threat
hcq
use
wide
ongo
well
design
clinic
trial
expect
provid
explicit
answer
near
futur
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
endoct
